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ABSTRACT 
 
Proteins are the effectors of cellular functions and the constituting elements of cellular 
signaling cascades. The ability to analyze the abundances and the dynamics of proteins is 
central to dissect cellular signaling and its effects on cell physiology. 
The aim of this thesis is to gain insight into protein level regulatory mechanisms that 
contribute to the development of cancer, by optimizing and employing targeted and large-
scale methods. Specifically, to examine mechanisms regulating protein stability, localization, 
protein-protein interactions, and to characterize targets of a protein phosphatase enzymatic 
activity. Additionally, to optimize a workflow for quantitative phosphoproteomics analysis 
with the goal of improving the sensitivity and lower the requirement in terms of sample 
quantity of current methods. 
Study I elucidated a mechanism by which S100A4 interacts with p53 in the nucleus thereby 
promoting its degradation, and the effects of this interaction on the growth and survival of 
lung and cervix adenocarcinoma cell lines, by employing targeted methods for the analyses of 
protein stability, protein localization and protein-protein interactions. 
Study II elucidated a mechanism by which TRAP promotes metastasis-related cell properties 
in breast cancer cells via the TGFβ-pathway and CD44, by a combination of proteomics and 
phosphoproteomics analyses with targeted methods. Furthermore, a moderate-depth 
phosphoproteomic profiling of TRAP overexpressing cells was achieved by peptide 
fractionation by high-resolution isoelectric focusing (HiRIEF) on IPG strips pH range 2.5-
3.7, and provided a list of putative targets of TRAP phosphatase activity. 
Study III developed a workflow for in-depth quantitative phosphoproteomics analysis based 
on high-resolution isoelectric focusing (HiRIEF) fractionation on a wide pH range (2.5-10). 
The workflow employs phospho-enrichment by titanium dioxide coupled with isobaric 
labeling by TMT, and provides for good analytical depth and sensitivity, requiring a low 
amount of starting material. Application of this workflow for the analysis of cervix 
adenocarcinoma cells HeLa revealed 1,264 novel phosphorylation sites, of which 165 
phospho-sites that are suggested to have a regulatory function during the mitotic phase, based 
on kinase-association analysis. 
In summary, the work presented in this thesis contributes to the collective effort of improving 
and applying targeted and large-scale methods for the analysis of protein level regulatory 
mechanisms, particularly by focusing on the optimization of a workflow for 
phosphoproteomics analysis. Development of these methods and improvements in integrating 
discovery and validation efforts, will be central in the coming years and offer unprecedented 
opportunities for increasing our understanding of life and to discover new treatments and 
cures for diseases.  
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 INTRODUCTION 
 
1 The hallmarks of cancer 
A seminal paper by Douglas Hanahan and Robert A. Weinberg published in 2000 defined six 
alterations in cell physiology that are essential for malignant cell growth, known as the 
hallmarks of cancer [1]. Two emerging hallmarks and two enabling characteristics were 
added in a second paper by the same authors published in 2011 [2]. The hallmarks include 
evading growth suppressors, inducing angiogenesis, deregulating cellular energetics, 
activating invasion and metastasis, sustaining proliferative signaling, enabling replicative 
immortality, avoiding immune destruction and resisting cell death, while the characteristics 
that enable tumor formation include genome instability and mutation and tumor-promoting 
inflammation (Figure 1). Despite the heterogeneity of human cancers, these hallmark 
features are shared by all human tumors and therefore provide a powerful theoretical 
framework to dissect the cellular processes underlying the development of malignancies.  
 
The doctoral work presented herein includes three studies, each of which is related to a 
different cancer hallmark or tumor-enabling characteristic: resistance to cell death, activation 
of invasion and metastasis and genome instability. These hallmarks will be discussed in 
paragraphs 1.1 to 1.3 of this section. The intent of these paragraphs is not to cover the subject 
Figure 1. Hallmark alterations and characteristics enabling cancer. 
Adapted from Cell. 2011 Mar 4;144(5):646-74, Hanahan D, Weinberg RA., “Hallmarks of cancer: the next generation”, 
doi: 10.1016/j.cell.2011.02.013, with permission from Elsevier. 
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exhaustively, but rather to provide essential notions about the hallmarks, as well as to discuss 
specific aspects that are relevant to frame the work presented in this thesis.  
Paragraph 1.1, related to Study I, will introduce fundamental concepts on tumors resistance to 
cell death and on the contribution of p53 inactivation to this cancer hallmark, as well as 
summarize the mechanisms behind p53 inactivation. Paragraph 1.2, related to Study II, will 
focus on the process of cell invasion and metastasis, particularly on the roles of TGFβ, CD44 
and the protein phosphatase TRAP. Paragraph 1.3, related to Study III, will discuss the basics 
of the cell cycle and mention main mechanisms of surveillance of the cell genome integrity 
that are exerted at different points of the cell cycle. 
1.1  Resistance to cell death – Inactivation of p53  
Cell death is a common event in the human body. Cells can activate a program where an 
ordered series of events leads to cell death, called apoptosis. Apoptosis occurs 
physiologically in many tissues of the human organism to facilitate tissue renewal and 
maintain the appropriate number of cells. Apoptosis is also triggered by abnormalities in 
several cellular systems, including DNA damage, aberrant signaling mediated by oncogenes, 
lack of survival factors or hypoxia [3,4]. 
Cancer cells ability to avoid the activation of the apoptotic program in response to these 
stimuli grants them a survival advantage when conditions are harsh (e.g. lack of nutrients or 
of oxygen due to poor blood supply). Additionally, disruption of the normal apoptotic 
program increases DNA replication errors, and consequently the mutational rate, which in 
turn accelerate the rate at which mutations that favor cell proliferation occur, therefore 
enhancing tumor development [1,2]. 
1.1.1 Functions of the p53 protein 
One of the main functions of the protein p53 is to activate the apoptotic program in case of 
errors in the cell genome or defects in the cell replicative machinery [5]. 
The p53 protein is normally present at very low levels in the cell. An increase in the level of 
p53 rapidly activates a series of events that leads to cell cycle arrest or to apoptosis. In order 
to maintain low levels of this protein, p53 is constantly degraded thus preventing its 
accumulation in the cell and activation of its function [6]. Main stimuli determining an 
increase in p53 levels include UV or ionizing radiations (causing double- or single-strand 
DNA breaks), hypoxia, lack of nucleotides and oncogene signaling (such as aberrant 
activation of the PI3K, Ras-Raf-MAPK pathway) [5,7].  
p53 functions as a transcription factor. Wild type p53 exists in the cell nucleus as a tetramer 
[8,9]. Increase of p53 levels and post-translational modifications of its C-terminal domain 
lead to p53 activity, resulting in the transcription of several target genes. Two well studied 
targets of p53 transcriptional activity are p21CIP1 [10,11], which activates a program that leads 
to cell cycle arrest, and MDM2, the E3 protein ubiquitin-ligase that targets p53 for 
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degradation [12–14]. Activation of MDM2 transcription by p53 establishes a negative 
feedback loop that keeps p53 levels low [15,16]. 
Besides p21CIP1 and MDM2, p53 induces the transcription of a large number of other genes, 
overall exerting two main effects [5,7]: 
1) cytostatic: growth arrest is induced to give time to the cell to repair errors in its DNA 
before allowing the cell cycle to proceed and cell division to occur. To help with this 
task, p53 also induces the expression of DNA repair genes. 
2) apoptosis inducer: in case of major damages to the DNA and inability of the cell to repair 
them, or in case of anoxia or severe imbalances in cellular signaling, p53 up-regulates the 
expression of pro-apoptotic genes as well as hinders the expression of anti-apoptotic 
genes. 
1.1.2 Regulation of MDM2-dependent p53 degradation and mechanisms of p53 
inactivation in cancer 
As mentioned in the previous paragraph, p53 is constantly degraded in the cells. The half-life 
of p53 is estimated to be around 20 minutes [17–19], therefore blockage of p53 degradation 
results in a rapid increase of p53 abundance in the cell. 
p53 degradation is mediated by the E3 ubiquitin ligase MDM2. Binding of MDM2 to p53 
immediately shuts off its transcriptional activity. Additionally, MDM2 catalyzes the addition 
of ubiquitin groups on the N-terminal region of p53, and mediates its export from the nucleus 
to the cytoplasm, where ubiquitinated p53 is degraded in the proteasome [12–14]. The protein 
ARF is another main regulator of p53 levels. ARF inhibits MDM2 activities by preventing its 
interaction with p53, either by sequestering MDM2 in the cytoplasm, or by targeting it to the 
nucleolus [20,21]. Cancer cells often show deregulation of either or both of these regulatory 
mechanisms. p53 wild type (wt) cancer cells often have both copies of the ARF genes 
inactivated, resulting in increased degradation of p53 by MDM2. Many cancers achieve a 
similar effect by overexpressing MDM2 [5].  
p53 function is often lost in cancer due to mutations of the p53 gene, which are displayed by 
30-50% of human cancers [22–24]. Contrary to the majority of tumor suppressor genes, 
which are mostly inactivated by frameshift or nonsense mutations, p53 is often found to be 
affected by mutations that lead to substitution of one of its amino acids (missense mutations) 
[25,26]. The resulting protein product is defective and cannot form a functional p53 tetramer. 
Thus, heterozygous frameshift or nonsense mutations are sufficient to mediate loss of p53 
function as the protein product of the p53 mutated allele will form a non-functional complex 
when associating with the protein product of the p53 wt allele. On the contrary, in the case of 
heterozygous loss-of-function mutations (such as deletions), the protein product of the other 
(wt) allele suffice to maintain p53 functions, therefore loss-of-function mutations of p53 are 
not common in cancer [23]. As a result of the formation of non-functional p53 tetramers, 
MDM2 transcription is also not activated in p53 mutant cells, with the result that the inert p53 
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protein accumulates in the cell [27]. p53 is instead present at very low levels in p53 wt 
tumors as the negative feedback loop enacted by MDM2 is preserved.  
1.1.3 The S100 family of proteins and p53 
S100A4 belongs to the S100 family of Ca2+-regulated proteins. The S100 family of proteins 
is composed of 21 members. The expression of multiple members of the S100 family is 
deregulated in different types of human cancers, including colorectal, pancreatic, lung, breast 
and prostate cancer [28], with each type of cancer being characterized by a different S100 
proteins expression signature. Overexpression of S100A4 is associated with aggressive 
disease and development of metastasis in several human cancer types, and particularly in 
melanoma [29], breast [30,31] and lung [32,33] cancer. Research conducted in our group 
demonstrated that the expression of S100A4 and S100A6 in different lung cancer cell lines is 
up-regulated in response to ionizing radiation in a p53-dependent manner [34].  
S100 proteins do not have any known enzymatic function, but are thought to regulate other 
proteins through direct interactions. Interaction of S100B with p53 is well studied in 
melanoma [35–37]. Several reports demonstrate the interaction of S100A4 with the 
cytoskeletal protein myosin IIA [38,39], possibly explaining the connection between S100A4 
and the development of metastasis. At the time we initiated Study I, S100A4 had been 
demonstrated to interact in vitro with p53 nuclear export signal domain [40,41]. This domain 
is connected with p53 degradation, as export to the cytoplasm is necessary for the targeting of 
p53 to the proteasome. At about the same time, an interaction between p53 and MDM2 had 
also been demonstrated [42]. These studies were pivotal for our investigation of the 
interactions between the S100A4 protein and p53 and MDM2 in cells, as well as for studying 
the impact of these interactions on p53 degradation, and the consequences on cellular 
proliferation and survival. Results from this research furthered the understanding of the roles 
of S100A4 in cancer. The reader is referred to the “Results and Discussion” section of this 
thesis for a summary of the results of Study I and of their relevance in the field. 
1.2 Activation of invasion and metastasis – Mediators of cellular invasion  
1.2.1 The invasion-metastasis cascade 
A metastasis is formed when cancer cells leave the primary site of a tumor, travel through the 
body’s blood and lymphatic vessels and form a colony in a new site of the organism. 
Metastases are the cause of 90% of cancer-related deaths [43]. The tendency to form 
metastasis as well as the preferred site of metastasis differ based on tumor type. For example, 
melanomas often form metastases, while brain tumors rarely do [4]. Common sites of 
metastases are the bones, the brain, the liver and the lungs [43,44]. Outgrowth of metastatic 
colonies at these sites disrupts normal tissue function and is therefore life threatening. 
Metastases are formed through a process named the invasion-metastasis cascade, which 
proceeds in several steps: local invasion, intravasation, transport through the circulation, 
arrest in a secondary site, extravasation and colonization of a new site in the organism. The 
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first steps of this process occur commonly, in fact metastasis-free patients often display a 
large number of cancer cells in circulation [45]. However, the metastatic process is 
inefficient; the rate-limiting step of this process is thought to be the colonization of a new site 
[46,47]. Execution of the steps of the invasion-metastasis cascade involve the acquisition by 
the migrating cell of a mesenchymal phenotype, the degradation of extracellular matrix to 
make space for invading cells and the reorganization of the migrating cell cytoskeleton and 
dynamic modulation of its adhesion to allow for cell movement [45]. A complex network of 
intracellular signals as well as signals between cells and the extracellular matrix contribute to 
the realization of these steps [48]. 
1.2.2 Epithelial-to-mesenchymal transition and local invasion 
The process of local invasion is well defined for carcinomas, which represents 90% of human 
tumors. Carcinomas are cancers that develop from epithelial cells. Epithelial cells form the 
tissues that line the inner and outer cavities of the human bodies. Epithelial tissues do not 
contain blood vessels and get nutrients from the underlying connective tissue, by diffusion 
through the basement membrane, a specialized type of extracellular matrix. Carcinomas form 
at the epithelial side of basement membranes; after an initial phase in which they grow 
locally, they may acquire the ability to breach through the basement membrane and invade 
the underlying connective tissue. This ability, termed local invasion, defines a malignant 
tumor [45].  
Local invasion is enabled by a change in the cancer cells’ transcriptional programs, that 
determines a shift from an epithelial to a mesenchymal phenotype (epithelial-to-mesenchymal 
transition, EMT). During EMT cells stop expressing E-cadherin and start expressing N-
cadherin. E-cadherin connects epithelial cells tightly to each other, forming ordered and stiff 
cells layers, while N-cadherin form weaker intracellular bonds that allow for cell motility, 
therefore permitting the cancer cells to break out of the ordered epithelial layer and move 
through the basement membrane into the underlying connective tissue [49]. Local invasion is 
also dependent on the secretion of matrix-metalloproteases (MMPs), which are synthesized 
by cancer cells after they have undergone EMT. MMPs digest the basement membrane 
providing cancer cells with extra space to expand, as well as with growth factors that are 
present in the proteinaceous matrix of the basement membrane itself. Ultimately, breaching 
through the basement membrane allows the cancer cells to reach the underlying connective 
tissue, where they get access to blood vessels [45]. 
EMT can be triggered by molecules derived from the connective tissue, such as TGFβ [50] or 
collagen-I [51,52]. Notably, cancer cells that have undergone EMT in response to TGFβ 
derived from the underlying connective tissue have been shown to be able to start produce 
TGFβ themselves and therefore become self-sufficient in maintaining the mesenchymal 
phenotype [53]. Another effector of EMT as well as a promoter of cell invasiveness is CD44, 
a cell receptor strongly involved in cellular adhesion [54].  
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1.2.3 Contrasting roles of TGFβ: a protein with tumor suppressor and tumor promoting 
capabilities 
TGFβ is a well-studied molecule able to exert contrasting effects on cells. As we mentioned 
in the previous paragraph, TGFβ can trigger EMT and contribute to the maintenance of cells 
mesenchymal phenotype, therefore contributing to the formation of metastases. In normal 
cells though, TGFβ acts as a growth repressor. Therefore cancer cells need to evade this 
effect of TGFβ to benefit from its invasion-inducing capabilities [53]. 
TGFβ acts by binding to its receptors on the cell surface, and triggering the phosphorylation 
and translocation to the nucleus of the Smad transcription factors [53]. Smads induce the 
transcription of numerous target genes, including the two CDK inhibitors p15INK4B and 
p21CIP1 [55–57], which halt cell cycle progression. This effect is counteracted by Myc, which 
represses the transcription of p15INK4B and p21CIP1 [53,58–60]; TGFβ though, is able to shut 
down Myc transcription [61,62], thereby keeping full control on cell cycle progression. TGFβ 
also trigger another series of events in cells independently from the Smad transcription 
factors (non canonical TGFβ signaling) [53]. Effector molecules stimulated by TGFβ include 
several proteins in the MAPK pathway (MAPK1, MAPK3, MAPK14 and JNK) [63–65], 
PI3K, AKT and mTOR [66], and several GTP-binding proteins (Ras, RhoA, Rac1 and 
Cdc42) [67]. Amplified activation of these non-canonical TGFβ effectors in response to 
TGFβ contributes to cancer development and progression. 
Several mechanisms are responsible for the resistance of cancer cells to the cytostatic effects 
of TGFβ, including: 
1. Overexpression of Myc, which in turn inhibits p15INK4B and p21CIP1 transcription through 
several mechanisms [56,68,69]. Myc overexpression can result from its transcription 
having become unresponsive to TGFβ [70], either because of deregulation of Myc 
transcription factors, or because of mutations in the Myc gene promoter leading to 
constitutive transcription [71] 
2. Inactivation of the pRb signaling pathway: when pRb is eliminated, the sole presence of 
p15INK4B is not sufficient to halt the cell cycle [72] 
3. Hyperactivation of the PI3K/AKT pathway, which results in inhibition of Smad3-
dependent p21CIP1 trascription [55,73–75] 
Once cancer cells have evaded its cytostatic effects, TGFβ instead promotes tumor 
development by increasing cell proliferation and cell invasiveness. There are several 
mechanisms responsible for these effects, many of which have not yet been fully elucidated. 
For example, TGFβ mediates increased cellular proliferation by inducing the expression of 
cytokines and growth factors, including IL-1, CTGF, PDGF, TGF-α, EGFR and PDGFR 
[53]. A plethora of mechanisms responsible for TGFβ-mediated EMT and metastasis have 
been demonstrated [53,76,77], including: 
1) Stimulation of EMT and metastasis through several molecules in the TGFβ canonical and 
non canonical pathways 
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2) Crosstalk between TGFβ and integrins: integrins have been shown to trigger EMT in a 
TGFβ-dependent manner in several types of cancer cells 
3) TGFβ-dependent dissolution of cellular tight junctions and disassembly of cell actin 
cytoskeleton, leading to induction of EMT 
4) TGFβ-induced production of factors mediating breakdown of mineralized bone, leading 
to enhanced osteolytic bone metastases 
Contributions of TGFβ to cell invasiveness are still being defined and are an active area of 
research and will be discussed in Study II of this thesis.  
1.2.4 CD44 participates in cancer cells EMT, adhesion, migration and metastasis 
CD44 is a cell receptor whose major ligand is hyaluronan, the most abundant component of 
the basement membrane. Binding of CD44 to hyaluronan regulates EMT and inhibition of the 
synthesis of hyaluronan reduces EMT and the formation of metastases [78,79]. Hyaluronan, 
CD44, TNFα and TGFβ have been shown to collaborate in inducing EMT. In this model, 
TNFα induces CD44 activation by promoting the synthesis of hyaluronan; CD44 in turn 
activates TGFβ receptor II and its downstream signaling cascade mediated by the Smads, 
resulting in EMT [80] (Figure 2). 
Additional CD44 ligands include osteopontin (OPN), FGF2, VEGF, HGF, collagen, laminin, 
Figure 2. A signaling pathway leading to EMT dependent on the crosstalk between CD44, 
TNFα and TGFβ. This scheme illustrates an example of crosstalk between several molecules, 
including CD44, leading to EMT. TNFα activates the transcription of hyaluronan synthase (HAS) 
mediated by protein kinase C (PKC). Hyaluronan binds and activates CD44 on the plasma membrane; 
activated CD44 in turn initiates the activation of TGFβ receptor II and its downstream signaling 
through the SMAD proteins, which ultimately induce EMT [80]. Reprinted by permission from Macmillan 
Publishers Ltd: Nature Reviews Cancer 11, 254-267 (April 2011), doi:10.1038/nrc3023, Margot Zöller,  “CD44: can a 
cancer-initiating cell profit from an abundantly expressed molecule?”, Copyright © 2011. 
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and fibronectin. Binding of CD44 to its ligands is involved in the assembly of an extracellular 
matrix that supports tumor cell adhesion [54] and induces the upregulation of other adhesion 
molecules, such as integrins [81]. Migrating tumor cells use CD44 to adhere and roll on 
endothelial cells during the initial steps of extravasation. CD44 is pushed at the leading edge 
of migrating tumor cells by the actin cytoskeleton, which bind to the CD44 cytoplasmic tail 
[82,83]. CD44 is also able to concentrate MMPs at the cell surface, which locally degrade the 
extracellular matrix and create space for the invading cells [84,85]. Activation of TGFβ 
through CD44-associated MMP9 has been demonstrated, resulting in enhanced invasion and 
metastasis, as well as increased osteoclast activity and bone resorption [86,87]. 
1.2.5 Tartrate resistant acid phosphatase (TRAP) and bone metastasis 
The bone is a plastic tissue whose turnover is regulated by two types of cells: osteoclasts, 
which have the function to breakdown mineralized bone, and osteoblasts, which have the 
function to reconstruct it. As much as 10% of skeletal bone mass is replaced every year. 
Osteoclasts break the bone down by first demineralizing it, and then by degrading the 
extracellular matrix which formed the scaffold for the calcium phosphate crystals, in a 
process termed bone resorption [88]. Metastasizing cancer cells manipulate osteoclasts and 
osteoblasts to remodel the bone in order to make space for their own growth. Breast cancer 
cells, for example, are able to activate the osteoclasts to form osteolytic metastases [76].  
Tartrate resistant acid phosphatase (TRAP) is the protein encoded by the human gene ACP5, 
and is expressed by actively resorbing osteoclasts, therefore being a marker for bone 
resorption [89]. Besides its expression in osteoclasts, TRAP is also highly expressed in 
several human cancers, including melanoma, breast and ovarian cancers [90,91] and is a 
marker for bone metastases [92–96]. Even though the connections between TRAP and the 
development of metastases are numerous, the understanding of the molecular routes 
mediating this function is fragmented. A few molecular mechanisms regulating and/or 
mediating TRAP actions have been demonstrated. TRAP modulates the phosphorylation of 
the focal adhesion kinase (FAK), resulting in increased invasion and metastasis of melanoma 
and breast cancer [97], and it is a transcriptional target of Forkhead box M, promoting 
hepatocellular carcinoma metastasis [98]. The fundamental questions of whether and how 
TRAP phosphatase activity is causally involved in the development of metastases remain 
unanswered. As of today, TRAP is known to dephosphorylate osteopontin and bone 
sialoprotein [99], but no other substrates of its phosphatase activity are known. Study II of 
this thesis addresses this question by analyzing the phosphoproteome and the proteome of 
breast cells overexpressing TRAP and of the same cells after reverting the increased TRAP 
expression by shRNA mediated knockdown. The reader is referred to the “Results and 
Discussion” section for this discussion. 
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1.3 Genome instability – Deregulation of progression through mitosis and 
chromosomal instability 
Cancer cells are characterized by a high degree of mutability of their genomes, which 
accelerates the rate at which these cells can acquire combinations of alleles advantageous for 
their proliferation and survival [2]. As a result of this increased mutability, cancer cells 
genomes are unstable. Normally, there are different mechanisms in place to halt the process 
leading to cell division when the DNA is damaged or errors occur during its replication, or 
when the chromosomes are in disarray prior to cell division. Inactivation of these 
mechanisms confers cancer cells genomic instability [100]. 
1.3.1 The cell cycle 
The ordered sequence of events leading to cell division is termed the cell cycle. The cell cycle 
is conceptually divided into four major stages (Figure 3). After cell division, cells enter a 
phase called G1 (first gap), where they make a decision on whether to grow or to enter a 
Figure 3. Stages of the cell cycle. 
Reproduced from “Wikipedia: The free encyclopedia. (2004, July 22). FL: Wikimedia Foundation, Inc. 
Retrieved on August 24, 2017, from https://commons.wikimedia.org/wiki/File:Animal_cell_cycle-en.svg 
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quiescent state, from which possibly they can differentiate. If the decision to grow is made, 
cells synthesize the nucleic acids required to duplicate their DNA and the other molecules 
necessary to form the components of two daughter cells. When all the necessary elements 
have been synthesized, different signals can trigger the crossing of a decision point in G1 
called restriction point (R-point), after which the cell is committed to proceed through the rest 
of the cell cycle and divide. After traversing the R-point, cells enter the S (synthesis) phase, 
during which their genetic material is replicated and then progress through a G2 (second gap) 
phase [101]. Finally, cell division into two daughter cells is performed during the mitotic (M) 
phase. The mitotic phase is further divided into prophase, pro-metaphase, metaphase, 
anaphase, telophase and cytokinesis [4].  
During the cell cycle, several surveillance mechanisms monitor each step and permit the cell 
to proceed to the next step only if the previous step has been completed successfully. In case 
of errors, these monitors arrest the progression through the cell cycle until the problems have 
been resolved. These monitoring mechanisms constitute the cell cycle checkpoints and can be 
summarized as [102]: 
• DNA damage checkpoint, at the G1/S transition: the cell does not enter the S phase if the 
genome is damaged 
• DNA damage checkpoint, during S phase: DNA replication is halted when errors in the 
replication occur or if the DNA is damaged, to give to the cell time to repair the damage 
• entrance to M-phase: if DNA replication is not completed, entrance into the M-phase is 
blocked 
• spindle assembly checkpoint (SAC): if the chromatids are not properly assembled on the 
mitotic spindle during pro-metaphase, the cell does not proceed to anaphase to avoid 
missegregation of the chromosomes to daughter cells  
1.3.2 Tight regulation of the progression through mitosis prevent errors in 
chromosomal segregation 
Alterations affecting different stages of the cell cycle contribute to cancer progression by 
providing growth, survival or transformation advantages to the cell. A main cell cycle 
deregulation is loss of the R-point in the G1 phase by inactivation of the pRb gene, which 
grants cancer cells unrestrained proliferative capability. The vast majority of human tumors 
display inactivation of the pRb pathway [103]. Another important surveillance mechanism, 
the SAC, in enacted during mitosis to halt mitotic progression until all chromosomes are 
correctly attached to the mitotic spindle [104,105]. Mitosis is a highly complex cell cycle 
stage, which proceeds in an orderly series of steps to ensure that errors in chromosome 
segregation are not made. Disruption of mechanisms governing the progression through the 
mitotic phase can result in chromosomal instability (CIN). CIN is defined as a persistently 
high rate of gain or loss of entire chromosomes or fractions of chromosomes during cell 
divisions [106,107]. About 85% of cancer cells characterized by CIN are aneuploid, which 
means that one or more of their chromosomes misses a copy or presents extra copies [4]. 
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As mentioned earlier, mitosis is divided into several phases: prophase, pro-metaphase, 
metaphase, anaphase, telophase and cytokinesis. Briefly, during prophase the centrosomes 
migrate to the opposite sides of the cell nucleus and start to polymerize tubulin to form 
microtubules; chromosomes condense and structures called kinetochores that will be sites of 
microtubules attachment are assembled at the chromosome centromeric region. During pro-
metaphase the nuclear envelope breaks down, so the microtubules produced by the 
centrosomes can reach and associate with the chromosomes kinetochores. When all 
chromosomes are attached to the spindle, with their sister chromatids attached to opposite 
spindle poles (bi-orientation), pro-metaphase is completed. Failure of proper attachment of all 
chromosomes to the mitotic spindle triggers the SAC. Mitosis continues with chromosomes 
alignment at an equal distance between the two spindle poles in metaphase (congression), 
after which sister chromatids are separated and pulled towards their respective pole 
(anaphase). Finally, the cell divides in two daughter cells (telophase and cytokinesis) [108]. 
In Study III, cells were treated with nocodazole, a small molecule inhibitor of tubulin 
polymerization that causes cell cycle arrest in mitosis [109]. Inhibition of tubulin 
polymerization by nocodazole results in the disruption of the mitotic spindle, which triggers 
the SAC. The SAC is enacted by the protein Mad2, whose soluble form is generated by 
binding to kinetochores that are not attached to microtubules. The soluble form of Mad2 is 
able to inhibit Cdc20, which is the initiator of the series of events that leads to the separation 
of the sister chromatids [104,105]. In summary, in the presence of nocodazole, unbound 
kinetochores prevent chromatid separation, thus the cell cycle is arrested in pro-metaphase. 
1.3.3 Regulation of cell cycle progression and mitotic phosphorylation  
Regulation of progression through the cell cycle is performed by cyclin/cyclin-dependent 
kinases (CDKs) complexes. Cyclins act as regulatory subunits and CDKs as catalytic 
subunits. Each type of cyclin pairs with a specific CDK: cyclins D bind CDK4/CDK6, 
cyclins E bind CDK2, cyclins A bind CDK2 or CDK1 and finally the cyclins B bind CDK1. 
Cyclin proteins level or availability is regulated by protein degradation or by intracellular 
localization, which restrict the expression and the activity of particular cyclins to the cell 
cycle stage that they promote. CDKs protein level instead is practically constant throughout 
the cell cycle, and their activity is regulated by the presence of the corresponding cyclin as 
well as by phosphorylation. Cyclin-CDK complexes activity can be abolished by CDK 
inhibitors, whose activity is enhanced by stressors such as DNA damage, or diminished for 
example by mitogenic signals [110]. 
The main regulator of the mitotic phase is the protein kinase CDK1. The control of mitosis 
involves more than 32,000 phosphorylation and dephosphorylation events [111], which drive 
cell rounding, condensation of the chromosomes, breakdown of the nuclear envelope, 
fragmentation of cell organelles, and finally the assembly of the mitotic spindle [112]. Not 
only do mitotic phosphorylations affect a very large number of substrates, but also display a 
high site occupancy (the proportion of proteins carrying the phosphorylation in a certain 
protein pool) compared to other cell cycle phases [113]. Most of these phosphorylation events 
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need to be reversed for the cell to exit mitosis and divide. The complex cyclin B1/2-CDK1 is 
responsible for phosphorylating a large number of mitotic substrates. In addition to CDK1, 
several other protein kinases are activated during the mitosis phase and govern various 
processes that are necessary for mitotic progression [114]. Phosphorylation events with 
regulatory functions are tightly controlled during mitosis both time- and space-wise (the latter 
by regulating the localization of the corresponding protein kinases). Though, the relevance 
and function of the majority of the phosphorylation events within the large network of mitotic 
phosphorylations is still unknown. It is hypothesized that a large number of the mitotic 
phosphorylation events serves to inhibit the function of proteins that are not involved in the 
processes occurring during mitosis [113]. Study III of this thesis addresses these fundamental 
questions on the functionality of specific protein phosphorylation events. 
2 Analyzing cellular signaling at the protein level 
2.1 Complexity of the proteome and mechanisms of protein level regulation 
The proteins are the effectors of cellular functions and the constituting elements of cellular 
signaling cascades. The ability to analyze the abundances and the dynamics of proteins is thus 
central to dissect cellular signaling and its effects on cell physiology. The ensemble of 
proteins expressed by a cell (proteome) is extremely complex [115]: the human genome 
contains approximately 20,000 protein coding genes; from those, it is estimated that 
approximately 100,000 distinct protein isoforms are generated through alternative splicing 
[116]. Additionally, the set of expressed genes varies across different cell lineages [117,118]. 
Transcriptomics analysis can provide information on which genes are transcribed and at what 
quantity, but transcripts abundances do not always correlate with protein abundances due to 
the actions of several post-transcriptional regulatory mechanisms [119–122]. Furthermore, 
protein activity and dynamics (e.g. enzymatic activity or protein-protein interactions) can be 
analyzed uniquely at the protein level. 
Several mechanisms of protein level regulation contribute to the complexity of the proteome 
(Figure 4). These mechanisms include: 
• Translational regulation (impacting protein levels) 
• Protein stability/turnover (impacting protein levels) 
• Protein cleavage events (impacting protein activities) 
• Protein-protein interactions (impacting protein levels and activities) 
• Subcellular localization (impacting protein levels and activities) 
• Post-translational modifications (PTMs, impacting protein activities and levels): more 
than 200 types of post-translational modifications have been listed [123]. 
The work presented in this thesis employs several methods for the analysis of mechanisms of 
protein level regulation in human cancer, including cellular treatments to assay protein 
turnover and immunoprecipitation and proximity ligation assay (PLA) to study protein-
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protein interactions (Study I); mass-spectrometry-based proteomics and phosphoproteomics 
to analyze protein abundance and phosphorylation status (Studies II and III). 
 The reader is referred to the Methods section for a description of the basic principles of these 
methods.  
2.2 Protein post-translational modifications – Protein phosphorylation 
Protein phosphorylation and protein dephosphorylation refer to the addition and removal of 
phosphate groups (PO43−) to and from proteins. Phosphate can react with the alkyl hydroxyl 
groups of serine and threonine side chains (pSer and pThr), and with the aryl hydroxyl group 
of tyrosine side chains, forming phosphate monoesters (pTyr) (Figure 5, top) [124]. 
Phosphate esters are very stable, and have an half-life of 1012 years at 25°C [125]. In 
eukaryotes, phosphorylation occurs mainly on serine, threonine and tyrosine residues 
[124,126] and is a major mediator of intracellular signaling transduction. Phosphate can also 
react with the imidazole groups of histidine side chains, and with the amine groups of lysine 
Figure 4. Sources of proteome complexity. Factors contributing to generate the complexity of 
proteomes include (clockwise from bottom left): translational regulation (use of alternative upstream 
open reading frames in mRNA translation or translation efficiency); alternative splicing; protein-
protein interactions; subcellular localization of proteins; post-translational modifications. Adapted by 
permission from Macmillan Publishers Ltd: Nature 537, 328–338 (15 September 2016) doi:10.1038/nature19947, 
“Proteome complexity and the forces that drive proteome imbalance”, J. Wade Harper & Eric J. Bennett, copyright 2016. 
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and arginine side chains, forming phosphoramidate bonds (Figure 5, bottom). 
Phosphoramidate bonds are rapidly hydrolyzed at high temperatures and at acidic pH [127]. 
Biochemical and proteomic procedures to study phosphoester amino acids (pSer, pThr and 
pTyr) commonly require these conditions, therefore the study of histidine phosphorylation 
has been very limited. Histidine phosphorylation has recently been shown to have regulatory 
roles in eukaryotic cells, but its abundance is still debated [128]. Finally, phosphate can also 
react with the thiol groups of cysteine side chains and with the carboxyl groups of aspartate 
and glutamate side chains; phosphorylation of these amino acids occur mainly in plants and 
in prokaryotes [124,126]. 
The fully protonated conjugate acid of phosphate is phosphoric acid (H3PO4); phosphoric 
acid has three constants of acid dissociation (pKa): 2.2, 7.2 (5.8 as an ester) and 12.4, each 
corresponding to the pH at which half of the molecules’ population undergoes proton 
dissociation [124]. This means that at physiological pH phosphoric acid donates one or two 
protons, and therefore possesses one or two negative charges. These pKas values are 
particularly low, making phosphorylated amino acids stronger acids than their 
unphosphorylated counterparts, as well as than any other unmodified amino acid. This unique 
property can be exploited to separate, and consequently enrich for, phosphorylated amino 
acids, as it will be discussed in more details in paragraph 1.2.4 in the Methods section. 
2.2.1 Protein kinases and protein phosphatases 
Phosphate groups are added to proteins by protein kinases and removed by protein 
phosphatases. The transfer of phosphate groups from ATP molecules to specific amino acids 
Figure 5. Common phosphorylated amino acids. 1-2-3) Phosphate esters, pSer, pThr and pTyr 
respectively. 4-5) Phosphoramidate bonds in two phosphohistidine isomers [247]. Reprinted from Amino 
Acids, “Focus on phosphohistidine”, January 2007, Volume 32, Issue 1, pp 145–156, P. V. Attwood et al., © Springer-
Verlag 2006, with permission of Springer. 
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in proteins is catalyzed by protein kinases. Phosphorylation is reverted by hydrolysis 
catalyzed by protein phosphatases. Eukaryotic protein kinases and phosphatases responsible 
for the phosphorylation and dephosphorylation of serine, threonine and tyrosine residues are 
well studied, and eukaryotic histidine protein kinases and phosphatases have also been 
identified [128]. At least 518 protein kinases and 189 protein phosphatases exist in human 
[129,130]. 
Eukaryotic protein kinases derive from a common protein kinase ancestor gene and therefore 
possess a conserved catalytic domain [131]. Protein kinases can be classified in 10 groups 
based on sequence and function of their catalytic domain [126]. The group of the tyrosine 
kinases includes 90 proteins; protein tyrosine kinases have evolved more recently than the 
other protein kinases, around the same time when multicellular organisms emerged. It is 
thought that the central role of tyrosine phosphorylation in transducing extracellular signals 
was fundamental to provide the inter-cellular communication functions necessary for the 
establishment of multi-cellularity [132]. Protein kinases target specific linear motifs on their 
substrates; recognition motifs are known for 179 (approximately 35%) of the protein kinases 
[133]. This specificity can be exploited to predict protein kinase-substrate interactions, 
expanded upon in paragraph 2.1.4 in the Methods section.  
The catalytic domains of protein phosphatases have several different evolutionary origins, 
unlike protein kinase domains [134,135]. Protein phosphatases often recognize their 
substrates based on docking interactions, rather than recognition of linear motifs at the site to 
be dephosphorylated [136] (Figure 6). 
Main modes of substrate recognition by protein phosphatases include [137]: 
1) Module-based: the phosphatase catalytic domain is positioned next to a domain capable 
of recognizing the substrate (e.g. a SH2 domain, recognizing a specific pTyr site) 
2) Short linear motif (SLiM)-mediated: the protein phosphatase contains one (or more) 
SLiM(s) that function as ligands for binding domains contained within the phosphatase 
substrate 
Figure 6. Mechanisms of substrate recognition by protein phosphatases. Adapted from FEBS Lett. 
(2012) 586(17):2732-9. doi: 10.1016/j.febslet.2012.05.008. “The human phosphatase interactome: An intricate family 
portrait”, Sacco F. et al. 
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3) Regulatory subunit-assisted: the protein phosphatase binds to an adaptor protein that 
targets it to its substrate; or, the protein phosphatase contains a SLiM that targets it to a 
subcellular localization where it can find specific substrates  
While about 5,700 protein phosphorylated residues have been associated with their upstream 
protein kinase [138], only 626 have been associated to their protein phosphatase [139]. The 
variety of mechanisms mediating protein phosphatases’ substrate recognition makes the task 
of enlarging the catalogue of protein phosphatase substrates particularly challenging. The 
work performed in Study II contributes to this effort by identifying a list of possible 
substrates of the protein phosphatase TRAP (see paragraph 2 in the Results and discussion 
section), by using a phosphoproteomics analysis. 
2.2.2 Protein phosphorylation impacts protein function and has a central role in 
intracellular signaling 
As illustrated in Figure 7, Protein phosphorylation affects protein function in different ways: 
1) Providing for a docking site or, in general, affecting protein-protein interactions. 
Protein phosphorylation can create docking sites for proteins that contain domains 
recognizing phosphorylated amino acids (phospho-binding domains) [126]. More in 
general, the negative charge carried by the phosphate group impacts the contact surfaces 
between proteins, and consequently may determine or impede protein-protein contacts 
[140]. 
2) Causing allosteric regulation. Allosteric regulation occurs when the modification or the 
binding of a ligand in one region of a protein affects the physical and/or chemical 
properties of another, distant site of the same protein [141]. Examples of regions known 
to allosterically regulate domain activity are the activation loops and the glycine-rich 
regions of protein kinases. Post-translational modifications found in these regions are 
therefore more likely to affect protein activity [140]. This principle is applied in Study III 
of this thesis to provide additional clues on the possible functionality of phosphorylation 
sites. 
 
Figure 7. Modalities by which protein phosphorylation impacts protein functions. Main 
mechanisms by which protein phosphorylation impacts protein function include: regulation of 
protein-protein interaction, allosteric regulation of protein activity, participation in a linear motif 
and regulation of protein bulk electrostatic properties. Adapted from Molecular Systems Biology (2013) 9, 
714, DOI 10.1002/msb.201304521, “Evolution and functional cross‐talk of protein post‐translational modifications”, 
Beltrao P. et al. 
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3) Creating linear motifs. Phosphorylation can control the functional state of a motif, by 
switching it to an “on” or “off” status, or altering its binding strenght [142]. Specific 
phosphorylated linear motifs are responsible for protein re-localization, degradation or 
cleavage [142,143]. 
4) Regulating the bulk electrostatics of the protein. The addition of several negative 
charges when multiple sites on a protein are phosphorylated impacts the ability of the 
protein to interact with other charged surfaces in the cell, such as the cell membrane 
[144], and determines major rearrangements of the protein structure. This mechanism has 
been hypothesized to be responsible for inhibiting protein functionality during the mitotic 
phase [113].  
Phospho-binding domains have a central role in the transduction of intracellular signals. The 
first of these domains to be discovered was the Src homology 2 (SH2) domain, which bind 
specific oligopeptide sequences containing a phosphorylated tyrosine [145]. As of today, 121 
SH2 domains have been identified; SH2 domains are characterized by a common 
tridimensional structure, but each domain binds a distinct pTyr-containing oligopeptide 
sequence. Other phospho-binding modules include the pTyr-binding (PTB) domain, and at 
least 14 distinct pSer/pThr binding domains, including the 14-3-3 and WW domains [126] 
(Figure 8). Phosphorylated amino acids flanked by specific oligopeptide sequences function 
as ligands for these domains, thereby determining the formation of a physical association 
between the proteins that carry them. Other interaction domains are able to recognize 
unmodified peptide motifs, such as the SH3 domain, which recognizes proline-rich 
sequences. The evolution of these interaction domains provided for a flexible system that 
could be employed by any cellular protein to form specific protein-protein interactions and is 
the foundation for the transmission of information occurring in intracellular signaling 
pathways [126]. 
 
Figure 8 Phospho-tyrosine and phospho-serine/threonine binding domains. Adapted from Jin et al., 
“Modular evolution of phosphorylation-based signalling systems”, Philosophical Transactions B, 2012 Sep 
19;367(1602):2540-55. doi: 10.1098/rstb.2012.0106, by permission of the Royal Society. 
2.2.3 Deregulation of phosphorylation signaling in cancer 
Phosphorylation is an extremely common post-translational modification; at present, 
phosphorylation has been identified on more than 17,000 human proteins [138]. Protein 
phosphorylation is centrally involved in the transduction of intracellular signals and in the 
regulation of cellular functions. Sustained phosphorylation signaling resulting from the 
aberrant activation of protein kinases drive several of the hallmark phenotypes of human 
cancer, including sustained proliferation, survival, invasion, deregulation of cellular 
metabolism, angiogenesis, and evasion of immune destruction [146].  
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Ninety one genes encoding for protein kinases have been identified as cancer drivers, and 
40% of those encode for receptor tyrosine kinases (RTKs) [147]. Deregulation of RTKs is 
particularly involved in sustaining proliferation signaling. Multicellular organisms depend 
upon the cooperation of large groups of cells mediated by intercellular communication; the 
functions of cells within tissues are coordinated in order to guarantee the wellbeing of the 
entire tissue and organism. Growth factors are major signaling molecules involved in 
intercellular communications. Growth factors act as mitogens, meaning that they provoke cell 
proliferation by favoring the progression through the R-point in G1. Several growth factors 
bind to receptor tyrosine kinases (RTKs) located on cell membranes to trigger cell 
proliferation. Protein tyrosine kinases are uniquely found in multicellular organisms (see 
paragraph 2.2.1 in this section), and have an exclusive role in receiving extracellular signals. 
Deregulation of protein kinases grants cancer cells the ability of sustaining proliferative 
signaling independently from extracellular signals [2]. Other protein kinases that act as 
drivers of cancer include TGFβ receptors; non-receptor tyrosine kinases (downstream of cell 
membrane receptors); intracellular protein kinases associated with the PI3K or MAPK 
pathways, which regulate multiple cellular functions; intracellular protein kinases regulating 
cytoskeleton organization, cell cycle progression, DNA repair or transcription [147]. 
Twelve protein phosphatases have been identified as being involved in the development of 
cancer. This group of protein phosphatases contains proteins acting either as oncogenes or as 
tumor suppressors, and some of these proteins phosphatases are cancer drivers [130]. 
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 AIMS AND OBJECTIVES OF THE PRESENT THESIS 
 
1 Overall aim of the thesis 
The overall aim of this thesis is to gain insight into protein level regulatory mechanisms that 
contribute to the development of cancer, by optimizing and employing targeted and large-
scale methods. Specifically, to examine mechanisms regulating protein stability, localization, 
protein-protein interactions, and to characterize targets of a protein phosphatase enzymatic 
activity. Additionally, to optimize a workflow for quantitative phosphoproteomics analysis 
with the goal of improving the sensitivity and lower the requirement in terms of sample 
quantity of current methods. 
 
2 Specific objectives 
Study I: 
• To investigate S100A4-p53 interaction and its consequences on p53 protein stability and 
on the proliferation and survival of lung and cervix adenocarcinoma cells, by employing 
targeted methods for the analyses of protein stability, protein localization and protein-
protein interactions. 
 
Study II: 
• To elucidate the molecular mechanisms underlying the promotion of cancer metastasis by 
the protein TRAP, and to characterize how TRAP affects cellular signaling and identify 
possible targets of its protein phosphatase activity in breast cancer cells, by proteomics 
and phosphoproteomics analyses coupled with targeted methods. 
 
Study III: 
• To develop a workflow for in-depth quantitative phosphoproteomics analysis using 
tandem mass tags (TMT) for multiplex quantification, a method rarely employed for 
phosphoproteomics analysis at the time the study was initiated. 
• To evaluate the analytical depth provided by high-resolution isoelectric focusing 
(HiRIEF) fractionation for phosphoproteomics analysis, by studying cervix 
adenocarcinoma cells treated with pervanadate or arrested in mitosis. 
  
  29 
 METHODS FOR THE ANALYSIS OF PROTEIN LEVEL 
REGULATION 
 
This section presents methods and technologies that were employed in this thesis to analyze 
mechanisms of protein level regulation. The basis of the methods and the rationale for their 
application will be discussed. The reader is referred to the papers for technical details on the 
methods, and for information on other methods that were used in the studies. 
1 Experimental methods 
1.1 Study I 
1.1.1 Protein turnover analyses 
Proteins are turned over in cells as a result of their synthesis in the ribosomes and their 
degradation by the proteasome or by the lysosomes and their secretion. The proteasome 
degrade proteins that have been modified by the addition of one or more ubiquitin molecules 
(polyubiquitin chains); the addition of ubiquitin is catalyzed by ubiquitin ligases. Protein 
ubiquitination is a highly regulated process; human cells contain more than 1,000 ubiquitin 
ligases [148] with distinct specificities for particular amino acid sequences (“degron” motifs) 
on target proteins [149]. The affinity of ubiquitin ligases for degron motifs can be modulated 
by PTMs of the degron motifs; additionally, the enzymatic activity of ubiquitin ligases can 
also be regulated, either by PTMs or by binding to scaffold or adaptor proteins. Modulation 
of protein degradation by these mechanisms affects a large array of cellular processes, 
including: elimination of misfolded proteins, regulation of DNA repair, transcription, 
replication, and chromosome cohesion/segregation, regulation of the dynamics and functions 
of several intracellular proteins, control of subunit stoichiometries within protein complexes, 
regulation of apoptosis, neurodegeneration and many others [150]. Alterations of protein 
degradation circuits, such as mutations that alter the levels or the activity of ubiquitin ligases 
or change their substrate specificity, are causally involved in many diseases, including cancer.  
In Study I, we employed cellular treatments that inhibit protein synthesis or protein 
degradation to analyze the rate of p53 degradation under different experimental conditions. 
Employed treatments include: 
• Cycloheximide: a protein synthesis inhibitor of bacterial origin, that functions by 
impeding the movement of tRNA and mRNA molecules in relation to the ribosome 
(blockage of translational elongation) [151]. 
• Nutlin-3A: a compound that specifically blocks p53 degradation, by inhibiting the 
interaction between the ubiquitin ligase MDM2 and p53 [152,153]. 
• MG132: a cell permeable molecule that inhibits the protease activity of the proteasome 
[154,155]. 
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Upon treatment with these compounds, p53 protein levels were measured by Western Blot 
(WB), to assess whether the employed experimental conditions affected p53 protein stability.  
1.1.2 Protein-protein interaction analyses 
As mentioned earlier, intracellular protein-protein interactions can impact protein 
localization, activity and stability (see paragraph 2.1 in the Introduction section). In Study I, 
we hypothesized that the degradation of p53 can be regulated via interaction with S100A4. In 
order to analyze the interaction between these two proteins, immunoprecipitation and 
proximity ligation assay were employed.  
Immunoprecipitation (IP) is based on the use of an antibody to precipitate a protein of 
interest, together with its interaction partners. In Study I, Western Blot analyses was 
employed to characterize the immunoprecipitated proteins. IPs are performed on protein 
extracts, therefore they do not provide information on the subcellular location of the 
identified interactions. Additionally, detergents employed for protein extraction can disrupt 
some protein-protein interactions. To avoid this undesired effect, proteins complex were 
cross-linked by incubating the cells with a 0.125% paraformaldehyde solution prior to protein 
extraction. Crosslinking works by introducing covalent bonds between proteins that are in 
close vicinity. The advantages of using formaldehyde are that it is a small molecule, and 
therefore it links only closely associated proteins, as well as its ease of use, as it freely crosses 
cell membranes (Figure 9) [156].  
The proximity ligation assay (PLA) is a method recently developed, which allows detection 
and quantification of protein complexes in intact cells, thus providing information on their 
subcellular localization. The method makes use of two antibodies attached to oligonucleotide 
molecules. When the two antibodies bind to two cellular proteins located in proximity to each 
other, the oligonucleotides can be ligated forming a small circle, which is then extended by 
rolling-circle amplification by a DNA polymerase. The resulting rolling-circle product is then 
Figure 9. Reaction of formaldehyde with proteins. 1) Formaldehyde reacts with amino acids 
containing primary amines (lysine), purines and thiols (cysteine). 2) Two modified amino acids react 
with each other forming a methylene (-CH2-) bridge. The cross-linking reaction also involves other 
functional groups such as amides, asparagines and guanidine and tyrosine carbon rings, but at slower 
rate [248]. Reproduced from Journal of oral and maxillofacial pathology (2012), 16(3): 400–405, DOI: 10.4103/0973-
029X.102496, “Chemical and physical basics of routine formaldehyde fixation”, Thavarajahet R. et al., copyright : © 
Journal of Oral and Maxillofacial Pathology. 
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hybridized with complementary fluorophore-labeled probes, resulting in the emission of 
strong fluorescent signals that can be captured as dots with a fluorescent microscope (Figure 
10) [157]. 
Microscopic images of the fluorescent dots can be overlaid with images of stained cellular 
nuclei and/or membranes from the same microscopic fields, to assign a nuclear or 
cytoplasmic localization to the protein complexes, as well as to count their number per cell. 
In Study I, PLA was employed to examine the interactions between S100A4 and p53, as well 
as between S100A4 and MDM2 and between p53 and MDM2. Since antibodies might bind 
other proteins than the one they are intended to (off-target binding), three different antibody 
pairs were employed to validate the interaction between S100A4 and p53.  
1.2 Studies II and III 
1.2.1 Mass spectrometry-based proteomics and phosphoproteomics analyses 
Mass spectrometry (MS) is a powerful and flexible technology for proteomics analysis. 
Bottom-up proteomics, which uses peptide identifications to infer protein identities, is the 
most widely employed proteomic approach to characterize proteins within complex 
Figure 10. In situ PLA. Two antibodies attached to oligonucleotide molecules bind to proteins that 
are localized in proximity. The oligonucleotides can therefore be ligated into a circular DNA 
molecule, which is then amplified by rolling-circle amplification (RCA). Finally, the rolling circle 
product is hybridized with complementary fluorophore-labeled probes, allowing for its detection. 
Reprinted from Methods, Volume 45, Issue 3, July 2008, Söderberg O. et al., “Characterizing proteins and their interactions 
in cells and tissues using the in situ proximity ligation assay”, Pages 227-232, Copyright 2008, with permission from 
Elsevier. 
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biological samples. Current MS-based proteomics technologies allow the identification and 
quantification of the relative abundances of more than 10,000 proteins in a cell [158]. 
The following paragraphs describe the steps of the workflows for bottom-up MS-based 
proteomics and phosphoproteomics analyses employed in Studies II and III. Large-scale 
phosphoproteomics analysis is challenging due to the low abundance and poor ionization 
efficiency of phosphorylated peptides [159]. To address these challenges, the workflows for 
phosphoproteomics analyses include phospho-enrichment by HiRIEF (Study II) or by 
titanium dioxide (Study III). 
1.2.2 Protein extraction and solubilization 
Proteins were extracted using a solution of 0.5% sodium deoxycholate (SDC) and 0.35% 
sodium lauroyl sarcosinate (SLS). These detergents are able to efficiently extract a wide 
variety of cellular proteins, including hydrophobic membrane-embedded proteins, which 
solubilize poorly [160]. Protein extraction and denaturation, was efficiently achieved by 
combining the use of these detergents with heating (95°C for 10 minutes) and chemical 
reduction and alkylation of cysteine residues, to disrupt disulfide bonds. Denaturation is 
necessary to render the protein accessible for enzymatic digestion. Detergents were removed 
by filter-aided sample preparation (FASP) [161]. This step is necessary for subsequent mass 
spectrometric analysis as detergents act as surfactants, impeding to the peptide ions to escape 
the electrospray droplets and enter the gas phase in the electrospray ionization (ESI) source 
(see paragraph 1.2.7 in this section), resulting in ion suppression. Recently, a novel method 
for detergent removal requiring a much shorter sample processing time and providing for 
higher experimental reproducibility, has been introduced. This method, employing 
paramagnetic beads and termed Single-Pot Solid-Phase-enhanced Sample Preparation (SP3), 
will likely be largely used in the coming years [162]. 
1.2.3 Protein digestion to peptides 
Proteins were digested to peptides using the endoprotease trypsin alone (Study II) or in 
combination with Lys-C (Study III). Trypsin cleaves polypeptide molecules at the C-terminal 
side of lysine and arginine residues, while Lys-C only cleaves at the C-terminal side of lysine 
residues. The combination of Lys-C and trypsin increases the efficiency of digestion; Lys-C 
cleavages at lysine sites mediate partial protein unfolding, which facilitates the access of 
trypsin to tightly folded protein regions [163]. Additionally, a high enzyme to protein ratio 
(1:25 w/w) was employed in Study III to improve the digestion efficiency of phosphorylated 
proteins, as negative charges carried by pSer and pThr residues reduce the accessibility to 
cleavage sites positioned in their vicinity [164]. A high digestion efficiency is important to 
limit the prevalence of peptides containing missed cleaved sites, which increase the 
complexity of the peptide mixtures to be analyzed, impacting negatively on the depth of 
identifications. Additionally, missed cleaved peptides introduces errors in relative 
quantification, as the relative proportion of cleaved to missed cleaved peptides tend to vary 
across samples. 
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1.2.4 Phospho-peptide enrichment 
Phosphorylation typically occurs on a small proportion of a protein pool, and consequently 
phosphorylated peptides are of low abundance. Most of serine and threonine phosphorylation 
events have been estimated to occur on less than 25% of the proteins in a protein pool (this 
proportion is referred to as fractional occupancy). The fractional occupancy is even lower for 
tyrosine phosphorylation events (less than 10%) [165]. Given their low abundance, 
phosphorylated peptides are often not identified when analyzing complex peptide samples. In 
order to increase the depth of phosphoproteomics analysis, several methods to enrich for 
phosphorylated peptides have been introduced. As tyrosine phosphorylation is particularly 
low abundant, specific enrichment methods have been introduced for the enrichment of 
tyrosine phosphorylated peptides, such as immunoprecipitation with antibodies targeting 
pTyr and purification using SH2 domain binders [166,167]. Very recently, it has been 
demonstrated that the employment of extensive pre-fractionation combined with high peptide 
loads can overcome the low abundance of phosphorylated species and allows to achieve good 
analytical depth without performing phospho-enrichment [168].   
Several approaches can be used for phospho-peptide enrichment; most of these approaches 
make use of positively charged metal ions which are able to bind to the negatively charged 
phosphorylated peptides. Employed metals include Fr3+, Ga3+, Zr4+ and Ti4+ for immobilized 
metal affinity chromatography (IMAC), and again titanium, in the form of TiO2 beads 
[166,169]; TiO2 beads were employed in Study III. The affinity of peptides for TiO2 beads 
correlates positively with the presence of acidic residues within the peptide sequence: the 
higher the number of acidic residues within a peptide and their acidic strength (measured by 
their pKa), the higher the affinity for TiO2 beads. The phosphate group of phosphorylated 
amino acids has a higher acidic strength than the side chains of the acidic amino acids 
aspartic acid and glutamic acid (phosphate group pKa is 2.2, while the pKas of the side 
chains of aspartic acid and glutamic acid are 3.67 and 4.25, respectively [170]). This means 
that in most pH conditions, phosphate groups have a high capacity to donate protons and 
therefore carry a negative charge (see paragraph 2.2 in the Introduction section). The more 
negatively charged phosphate groups on a peptide, the higher the affinity for TiO2. 
Consequently, the degree of binding affinity to TiO2 beads proceeds in the order: multiply 
phosphorylated peptides > singly phosphorylated peptides > non-phosphorylated peptides 
containing acidic residues [171]. In Study III, two parameters were adjusted to increase the 
specificity of the binding of TiO2 beads to phosphorylated peptides: 
• pH conditions employed for the binding. In Study III a solution containing 6% 
trifluoroacetic acid (TFA) (pH ≅ 2) was employed for binding phospho-peptides to TiO2 
beads. At this pH the majority of Asp and Glu side chains are protonated and therefore 
neutral (no negative charge), while the phosphate group, whose pKa is 2.2, is negatively 
charged and can be specifically bound by the TiO2 beads. 
• Proportion of TiO2 beads to peptides. The availability of binding sites on the TiO2 
beads impacts the equilibrium of bound versus unbound molecules. A high proportion of 
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TiO2 beads to peptides results in the presence of residual free binding sites after high 
affinity peptides-beads interactions have taken place (i.e. phospho-peptides-beads 
interactions). In that case, low affinity interactions between residual free binding sites and 
non phosphorylated peptides may take place. On the other hand, if the proportion of TiO2 
beads to peptides is too low, there aren’t enough sites on the beads to bind the 
phosphorylated peptides. In Study III a ratio of TiO2 beads to peptides of 1:4 was 
employed, which was previously shown to provide for a good binding specificity [171]. 
1.2.5 Relative quantification by LC-MS: metabolic labeling by SILAC and isobaric 
labeling by TMT 
Two methods for relative quantification were employed: stable isotope labeling with amino 
acids in cell culture (SILAC, Study II), and tandem mass tags (TMT, Study III). Both 
methods allow for multiplex analysis, which means that multiple samples can be analyzed in 
a single LC-MS run. For multiplexing, samples from different experimental conditions are 
labeled and pooled prior to MS analysis. SILAC multiplexing capability is limited to two or 
three samples (two were used in Study II), whereas TMT allow to simultaneously quantify 
ten samples. 
In Study III, TMT labeling was performed after phospho-enrichment. Phospho-enrichment 
highly reduces the quantity of peptides per sample, therefore reducing the amount of TMT 
reagent required for labeling (a single set of TMT reagents was employed in Study III). For a 
detailed discussion of the basis of SILAC and TMT labeling, refer to published literature 
([172], [173]). 
1.2.6 Sample pre-fractionation by high-resolution isoelectric focusing (HiRIEF) and its 
application to phosphoproteomics analysis 
Human cell proteomes are constituted by a very large number of chemically diverse proteins 
generated as a result of differential gene expression, alternative splicing, post-translational 
modifications and cleavage events (see paragraph 2.1 in the Introduction section), whose 
concentrations span seven orders of magnitude [174]. Additionally, protein digestion into 
peptides further increases the number of distinct molecular species present in the sample. 
Such complexity, both in terms of number of different molecules and in terms of their 
abundance, makes the task of identifying all of the molecules contained in a sample very 
challenging, disfavoring in particular the detection of low abundant proteins. Sample pre-
fractionation is a widely employed approach to increase the analytical depth of proteomics 
analyses based on reducing the complexity of the samples to be analyzed by LC-MS [166]. s 
discussed above, phosphorylated proteins are of particularly low abundance, and therefore 
chromatographic pre-fractionation is often employed to improve their detection. Commonly 
employed pre-fractionation methods for phosphoproteomics analysis include Strong Cation 
Exchange (SCX) and high-pH reversed phase chromatography [175,176].  
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In Studies II and III of this thesis, HiRIEF was employed as a pre-fractionation method. 
HiRIEF separates peptides based on their isoelectric point (pI), using immobilized pH 
gradient (IPG) strips with varying pH ranges. After focusing on IPG strips, the peptides are 
extracted into 72 fractions, which are then analysed individually by LC-MS. Generated 
fractions are highly orthogonal, as the majority of peptides (typically 85-90%) are identified 
in one or at most two consecutive fractions. Analysis of the generated fractions by LC-MS 
results in an in-depth profiling of the cellular proteome [177].  
Study II and Study III of this thesis describe for the first time the application of the HiRIEF 
fractionation method for phosphoproteomics analysis. At the time this thesis work was 
initiated we intended to test whether separation of peptides using a novel, prototypical, IPG 
gel strip with an “ultra-acidic” pH range (2.5-3.7) would be an efficient strategy to enrich for 
phosphorylated peptides. The rationale behind this idea is that phosphorylation decreases the 
pI of peptides due to the low pKa of the phosphate group (see paragraph 2.2 in the 
Introduction section). This idea had been tested before [178,179], but never with a separation 
technique with a high resolving power like HiRIEF. In Study II, we employed ultra-acidic 
IPG strips to separate samples containing 1 mg of peptides derived from breast cancer cells 
(Figure 11A). As it will be expanded upon in the Results section (paragraph 2), this approach 
Figure 11. Workflows for phosphoproteomic analysis based on HiRIEF. A) Phosphoproteomics 
analysis based on the enrichment using a “ultra-acidic” IPG strip. B) TiO2 enrichment is performed 
prior to fractionation of the samples on both the “ultra-acidic” and wide pH range (3-10) IPG strip, 
resulting in a high analytical depth. Adapted from “Tartrate-resistant acid phosphatase (TRAP/ACP5) promotes 
metastasis-related properties via TGFβ2/TβR and CD44”, Reithmeier A, Panizza E. et al., BMC Cancer (2017). In press; 
and from Scientific Reports 7, Article number: 4513 (2017), doi:10.1038/s41598-017-04798-z, “Isoelectric point-based 
fractionation by HiRIEF coupled to LC-MS allows for in-depth quantitative analysis of the phosphoproteome”, Panizza E. et 
al.  
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resulted in a limited analytical depth, which then motivated us to start the optimization of a 
more complex workflow. Such effort resulted in the method presented in Study III, where 
peptides are enriched with TiO2 beads prior to fractionation on IPG strips with pH range 2.5-
3.7 and 3-10 (Figure 11B). Employment of the wide pH range 2.5-10 allowed for the 
identification of a large number of phospho-peptides with varied amino acid compositions 
and number of phosphorylations. 
1.2.7 Phosphoproteomics analysis by LC-MS/MS using Orbitrap mass spectrometers 
Phosphoproteomics analysis was performed using a LTQ Orbitrap Velos mass spectrometer 
in Study II, and a Q Exactive mass spectrometer in Study III. We will review here the main 
components of the instrumental setups employed in these studies as well as highlight the 
differences between the two instruments. 
1) Nanoflow reversed-phase liquid chromatography (nano LC) system, coupled online to the 
mass spectrometer. Even after pre-fractionation, the degree of complexity of peptide 
mixtures derived from human cell samples is still very high. Separation by reversed-phase 
LC prior to MS analysis further simplifies the sample, thereby contributing to increase the 
analytical depth. Introduction of nano LC systems brought about major improvements for 
modern MS-based proteomics analysis [180]. The term nano LC derives from the rate of 
injection flow that these systems provide, which is on the order of nanoliters/minute. 
Such a low rate of injection flow permits the coupling to the nano-electrospray ionization 
(ESI) source, which in turns provide for high sensitivity due to the small size of the 
droplets it produces. Nano LC systems make use of chromatographic columns with a very 
small internal diameter. For this thesis work, chromatographic separation was performed 
on a 15 cm long C18 PicoFrit column with 100 µm of internal diameter in Study II (rate 
of injection flow 4 µl/min), and on a 50 cm long nano EASY-spray C18 column with 75 
µm of internal diameter in Study III (rate of injection flow 250 nl/min).  
2) Nano-ESI source: ESI is a so-called “soft” ionization system, as it can generate molecular 
ions without significant fragmentation, allowing the anaysis of intact polypeptides by MS 
[181].  
3) Mass analyzer: both the LTQ Orbitrap Velos and the Q Exactive instruments are 
equipped with an high-resolution Orbitrap mass analyzer. The design of the Orbitrap 
mass analyzer allows for high resolution (the capacity to distiguish two peaks whose m/z 
differ by a very small value) and accurate mass detection [182]. The LTQ Velos also 
performs mass analysis in a ion trap for the the fragment ions produced by collision-
induced dissociation (CID). Ions are selected for fragmentation using a quadrupole 
analyzer in Q Exactive instruments and using a ion trap in the LTQ Velos. Ion selection is 
faster in quadrupole analyzers than in ion traps [183]. 
4) Collision chamber: for MS2 analysis, ion fragmentation is performed by collision with 
gas molecules (typically N2) in a collision chamber. The LTQ Velos and the Q Exactive 
are equipped with a different set of collision chambers: the LTQ Velos contains both a 
ion trap (used for CID)  and an higher-energy collisional dissociation (HCD) collision 
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chamber, while the Q Exactive contains only a HCD collision chamber. There are several 
differences between those two fragmentation methods. Compared to CID, HCD produces 
more ion fragments, resulting in higher quality of the MS2 spectra. Additionally, CID 
fragmentation does not produce fragments ions with a m/z <= 0.3*(m/z)precursor ion [184] 
resulting in a loss of information on low-mass m/z fragment ions. As reporter ions from 
isobaric labels such as TMT have a very low mass (the largest m/z is 131), HCD is the 
fragmentation method of election for isobaric labeling-based relative quantification. 
When operating in CID (collision-induced dissociation) mode, the LTQ Velos performs 
ion selection, fragmentation and mass analysis sequentially in the ion trap. Instead, the Q 
Exactive only operates in HCD (higher-energy collisional dissociation) mode, using the 
Orbitrap for mass analysis. This means that is is able to fill ions for fragmentation in the 
HCD collision chamber while scanning the fragments generated by the previous 
fragmentation event in the Orbitrap. Finally, fragment ions produced by HCD are 
analyzed at high resolution in the Orbitrap, while fragment ions produced by CID are 
detected at low resolution in the ion trap [185]. Detection in the ion trap is faster than in 
the Orbitrap.  
2 Computational methods for the analysis and interpretation of large-scale 
proteomics and phosphoproteomics data 
Quantitative large-scale proteomics and phosphoproteomics analyses generate datasets 
containing thousands of variables measured across several experimental conditions. 
Appropriate statistics and bioinformatic approaches are fundamental to analyze and interpret 
these large-scale datasets in order to formulate biological hypotheses. Some of the key 
computational approaches employed in Studies II and III of this thesis are summarized in the 
following sections. 
2.1 Studies II and III 
2.1.1 Hierarchical clustering 
Hierarchical clustering is a method that allows for the grouping of sets of observations based 
on their similarity. In Studies II and III, sets of observations include the expression levels of 
proteins or phospho-sites across different experimental conditions. By grouping similar sets 
of observations, it is possible to find clusters of proteins (or phospho-sites), whose expression 
(or phosphorylation level) is regulated similarly across experimental conditions. Proteins (or 
phospho-sites) participating in the same cellular processes or that are part of a protein 
complex are often contained in such co-regulated clusters, therefore hierarchical clustering is 
a powerful approach for the interpretation of large-scale data.  
In hierarchical clustering, clusters of observations are organized in several levels based on the 
degree of similarity between clusters, forming a tree-shaped diagram called a dendrogram. 
Dendrograms are built in a step-wise manner. At the lower level of a dendrogram, each single 
observation constitutes a cluster. A distance representing the degree of similarity between 
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each pair of observations is then calculated using a function (distance metric), and the two 
most similar observations are joined into a new cluster. The similarity between this new 
cluster and each of the other (old) clusters is then calculated (based on a certain linkage 
method) and the two most similar clusters are joined again; this step is repeated until all 
observations are joined into a single cluster. This bottom-up clustering approach is termed 
agglomerative clustering. In the resulting dendrogram, the height of each node is proportional 
to the degree of similarity between the two clusters it joins: the higher the node, the less 
similar the clusters (Figure 12). 
 
Different approaches can be employed to calculate the distances between observations (by a 
distance metric) and between clusters (by a linkage method). In Study II and III of this thesis 
Euclidian distance was employed as distance metric and complete linkage was employed as 
linkage method [186].  
Distance metric – Euclidian distance 
Euclidian distance is defined as: 
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Figure 12. Dendrogram illustrating the arrangement of the clusters produced by hierarchical 
clustering based on Euclidian distance and complete linkage of ten observations. Ten 
observations derived from three experimental conditions measured in replicates (four, three and three 
replicates each) are clustered using Euclidian distance as distance metric and complete linkage as 
linkage method. Based on the dendrogram arrangement and node height, it is possible to observe that 
replicates of the same experimental condition cluster together, as well as that the cluster containing the 
three mitotic arrested samples differs the most compared to all of the other clusters. The color coding 
represents the cellular treatment: red - untreated samples; blue - pervanadate treated samples; green - 
mitotic arrested samples. Adapted from Scientific Reports 7, Article number: 4513 (2017), doi:10.1038/s41598-017-
04798-z, “Isoelectric point-based fractionation by HiRIEF coupled to LC-MS allows for in-depth quantitative analysis of the 
phosphoproteome”, Panizza E. et al.     
(1) 
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where (1): 
- x and y are vectors, each containing a set of observations (e.g. two vectors each 
containing the expression levels of a protein, or of a phospho-site, across different 
experimental conditions) 
- d(x,y) is the distance between the two vectors (sets of observations) 
- i is each observation in a set (e.g., each sample or replicate) 
- n is the number of observations per set (e.g. the number of samples or replicates) 
Euclidian distances always have a positive value, as the differences between each pair of 
measurements are squared. Another distance metric commonly used for hierarchical 
clustering is Pearson correlation; Pearson correlation coefficients have values ranging 
between -1 and 1, where -1 indicates a negative linear correlation, 0 indicates no correlation, 
and 1 indicates a positive linear correlation. Considering two sets of observations (e.g. two 
proteins) with a similar pattern of expression, Euclidian distance increases with the difference 
between the average of the two proteins expression level (different magnitude of regulation). 
The Pearson correlation coefficient instead would be close to 1 even in case the magnitude of 
regulation is different between the two proteins, as it expresses the existence of a linear 
correlation between the two sets of observations. Therefore, Euclidian distance will have a 
larger value in case of proteins regulated in the same direction (both up-regulated or both 
down-regulated) but to a different extent (different magnitude of regulation), than in the case 
of proteins regulated in the same direction and at the same extent, while the Pearson 
correlation coefficient will not differ. Therefore, Euclidian distance separates proteins (or 
phospho-sites), based not only on the pattern but also on the magnitude of expression. For 
this reason it was chosen for the analyses of the data from Study II and Study III of this 
thesis.  
Linkage method – Complete linkage 
Complete linkage is a method to calculate cluster distance, that defines the distance between 
two clusters as the longest distance between any two members of each of the two clusters. In 
other words, the distance between the two most dissimilar observations in each cluster 
defines the distance between the clusters. Other commonly used linkage methods include 
single linkage and average linkage, where the distance between two clusters are defined 
respectively as the shortest or as the average distance between the members of two clusters 
[187,188].  
2.1.2 Gene ontology enrichment analysis 
The gene ontology (GO) project provides a database of gene annotations describing the 
functionality of genes. This resource was employed in Studies II and III to examine the 
functionality of the identified proteins. In GO, gene functionality is described using terms 
belonging to three separate categories: biological process, molecular function and cellular 
component. Biological process terms describe the biological objective to which a gene or 
protein contributes. Molecular function terms describe the activities carried out at the 
 40 
molecular level by a protein. Cellular component terms describe the parts of a cell or of its 
extracellular environment where a protein is present and/or active. Biological processes are 
accomplished through the execution of one or more molecular functions [189,190]. GO terms 
are organized hierarchically: child terms describe specialized processes that contribute to 
master term processes. For example, child terms of “cell cycle process” include: “cell cycle 
phase transition”, “cytokinesis”, “attachment of spindle microtubules to kinetochore”, 
“centrosome duplication”, “centrosome separation”, and so on. As of today, the GO database 
contains 44,898 terms. 
In Studies II and III, the GO database was employed to investigate whether the sets of 
proteins or phospho-sites that were differentially regulated in the examined experimental 
conditions were enriched in particular functions, as compared to the set of all proteins 
expressed in the studied cells. In order to perform this analysis, the terms describing the 
subset of regulated proteins (target set) are compared to the terms describing all the proteins 
identified in the analysis (background set). Over- or under-representation of GO terms in the 
target set compared to the background set were evaluated in terms of significance and fold-
enrichment using the web tool GOrilla [191,192]. GO terms that are enriched in the target set 
represent the main cellular processes and functions that are regulated in the examined 
experimental conditions.  
2.1.3 Protein-protein interaction network analysis 
Protein-protein interaction analysis allows to infer the function of proteins based on their 
association with other proteins. For example, proteins displaying a high degree of 
connectivity tend to have important regulatory functions, and groups of highly connected 
proteins are usually involved in the same processes [192]. In Studies II and III, protein 
interaction networks were visualized using the software Cytoscape [193]. In protein-protein 
interaction networks, proteins are represented as nodes connected by edges representing some 
type of association between the proteins. The definition of association between proteins 
depends on the database used for the analysis. 
In Study II, the database STRING was used to derive information on protein-protein 
interactions. The confidence of each protein-protein interaction contained in the database is 
expressed by a probability score, termed “combined score”, which ranges between 0 and 1 
(no confidence to very high confidence). The combined score is a corrected score computed 
combining the probabilities derived from the different evidences available for an interaction 
[194]. STRING takes into account 7 types of evidences for protein-protein interactions: 
experimental (e.g. derived from biochemical, biophysical or genetic experiments); database-
derived (mainly from pathway databases, evaluated by a human expert curator); text mining 
(using Pubmed); co-expression (based on large-scale microarray and RNAseq data); 
neighborhood (assigned based on the conservation across species); fusion (assigned based on 
the existence of at least one organism where the pair of proteins considered has fused into a 
single protein-coding gene); co-occurrence (assigned based on the co-occurrence of the pair 
of genes examined in several organisms) [195,196]. In Study II, protein-protein interactions 
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with a combined score of at least 0.6 (representing a medium-high confidence of interaction) 
were employed in the analysis. 
In Study III, the Cytoscape plugin PhosphoPath was employed for analysis [197]. 
PhosphoPath renders a phosphorylation site-specific visualization of the data; proteins and 
phospho-sites are represented as separate nodes. Phospho-site nodes can be colored based on 
the phospho-site quantitative information, therefore providing for an efficacious 
representation of phosphoproteomics data. Each phospho-site is connected to the protein on 
which it occurs by an edge. Edges are also present between proteins that interact with each 
other (based on BioGrid [198]) and between protein kinases and phospho-sites that are 
known to be their substrate (based on the PhosphoSitePlus database [199]).  
2.1.4 Prediction of protein kinase-substrate association strength and the identification 
of putatively functional phosphorylation sites 
NetworKIN was employed in Study III to obtain scores expressing kinases-phospho-sites 
association strength [200], as a means to predict phospho-site functionality [201]. The 
rationale underlying this approach is that a strong and highly specific association with a 
protein kinase is necessary to mediate quick and precise phosphorylation events (as 
regulatory phosphorylation events typically are). Therefore, the strength of association with 
protein kinases can be used as a predictor of phospho-site functionality. 
NetworKIN scores combine two parameters to represent the strength of association between a 
phospho-site and a protein kinase: STRING scores (based on known protein-protein 
interactions [202]), and NetPhorest scores (based on the degree of matching between the 
sequence around the phosphorylated site and the motif recognized by the protein kinase 
[133]). NetworKIN reports the probability of association between 48,003 phosphorylation 
sites and 207 protein kinases. NetworKIN scores do not exist for the remaining 311 protein 
kinases due to lack of information on their interaction partners and/or on the motif they 
recognize on their substrates.  
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 RESULTS AND DISCUSSION 
 
1 Study I - S100A4 interacts with p53 in the nucleus and promotes p53 
degradation. 
S100A4 is overexpressed in several types of cancer and its expression is associated with poor 
prognosis and the development of metastasis [203].  A study conducted by Orre et al. had 
demonstrated p53-dependent expression of S100A4, as well as regulation of S100A4 in 
response to ionizing radiation [34]. Several studies had demonstrated an interaction between 
S100A4 and p53 by in vitro assays [40,204–208], but the interaction had never been shown in 
cells. In this study, we investigated the interaction between S100A4 and p53, and its 
consequences on p53 stability and on the growth and survival of the lung and cervix 
adenocarcinoma cell lines A549 and HeLa. 
The main findings from the study include: 
• S100A4 interacts with p53 in the nucleus of A549 and HeLa cells. 
• S100A4-p53 interaction increases upon inhibition of p53 proteasomal degradation (by 
the MDM2 inhibitor Nutlin-3a or by the proteasome inhibitor MG132). 
• S100A4 interacts with MDM2 in A549 cells, and the interaction between p53 and 
MDM2 increases upon inhibition of p53 proteasomal degradation by the proteasome 
inhibitor MG132. 
• p53 protein but not transcript levels are increased upon knockdown of S100A4 in A549 
and HeLa cells. 
• p53 degradation rate is decreased upon knockdown of S100A4. 
• The cell cycle arrests in G1 in response to S100A4 knockdown. 
• Upon S100A4 knockdown, apoptosis increases and anchorage-independent growth 
decreases in response to cisplatin. 
S100A4 was shown to interact with both p53 and MDM2 by PLA. A possible dynamic of 
these interactions might be that S100A4 binding to p53 favors its subsequent interaction with 
MDM2, thereby promoting the degradation of p53. Additional analyses would be necessary 
to clarify whether the three proteins exist as a complex or if these interactions occur 
sequentially. Furthermore, the interaction between S100A4 and MDM2 was demonstrated by 
PLA but was not confirmed by IP. Unbiased investigation of S100A4 interaction partners by 
MS analysis might clarify the nature and dynamics of these interactions, as well as possibly 
reveal additional S100A4 interaction partners.  
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2 Study II - Tartrate-resistant acid phosphatase (TRAP/ACP5) promotes 
metastasis-related properties via TGFβ2/TβR and CD44 in MDA-MB-231 
breast cancer cells. 
The protein phosphatase TRAP is overexpressed in several human cancers and is a marker for 
bone metastases [90–96].  In order to investigate the mechanisms mediating TRAP effects in 
cancer, we created three models: MDA-MB-231 breast cancer cells overexpressing TRAP 
(TRAP3high cells), and the same cells where TRAP overexpression was reverted using two 
different shRNA sequences (sh2 and sh3+4 cells). The proteome and phosphoproteome of 
these cell lines, as well as their phenotypes, were profiled and the main findings include: 
• MDA-MB-231 cells display increased anchorage-independent growth, increased 
proliferation, migration and transwell invasion upon TRAP overexpression. 
• Phosphoproteomics and proteomics analyses demonstrate a regulation of cellular 
adhesion and extra-cellular matrix organization processes upon perturbation of TRAP 
levels. 
• Regulated processes involve several proteins in the TGFβ pathway, as well as three 
highly up-regulated phospho-sites on CD44.  
• The proliferation and migration of TRAP overexpressing cells is reduced upon TGFβ2 
and TGFβ receptor 1/2 (TβR1/2) inhibition. 
• The proliferation of TRAP overexpressing cells is reduced upon blockage of CD44  
• 116 phospho-sites significantly down-regulated upon TRAP overexpression were 
identified. The twenty top down-regulated phospho-sites are reported in Table 1 
The 116 phospho-sites down-regulated in response to TRAP overexpression are candidates to 
be targets of TRAP phosphatase activity, but independent analyses would be necessary for 
their validation. Osteopontin and bone sialoprotein, which were previously described to be 
targets of TRAP [99], were not identified as dephosphorylated in response to TRAP 
overexpression in this study. The study might have failed to identify these proteins due to the 
limited analytical depth of the phospho-analysis (3,290 unique phosphorylation sites 
identified), which might have also hindered the identification of additional TRAP targets. As 
discussed in paragraph 1.2.6 in the Methods section, in this study the enrichment of phospho-
peptides was solely based on HiRIEF fractionation using an ultra-acidic IPG strip (pH range 
2.5-3.7). Phospho-peptides with such an acidic pI are mostly multiply phosphorylated 
peptides, or singly phosphorylated peptides containing a high number of acidic residues. 
Singly phosphorylated peptides with mildly acidic or basic amino acid composition are not 
identified by this approach, posing a major limitation to achieving a good analytical depth 
(Figure 13A). Besides those technical limitations, an additional challenge of identifying the 
targets of a protein phosphatase is that the abundance of the corresponding phospho-peptides 
is lowered (as they are dephosphorylated). In the case of a SILAC experiment, as the one 
utilized here, the control sample is the primary contributor to their quantity in the 
experimental sample.  
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3 Study III - Isoelectric point-based fractionation by HiRIEF coupled to LC-
MS allows for in-depth quantitative analysis of the phosphoproteome. 
 
The low abundance of phosphorylated proteins constitutes a major challenge in achieving a 
good analytical depth in phosphoproteomics studies. This study presents an optimized 
workflow for phosphoproteomics analysis based on fractionation by HiRIEF on a wide pH 
range (IPG 2.5-3.7, “ultra-acidic” strip; and IPG 3-10 strip). A low amount of peptides per 
sample (300 µg/sample) was employed for phospho-enrichment with TiO2, followed by 
labeling with TMT. Performance of TMT labeling after TiO2 enrichment limits the amount of 
TMT reagent required, therefore considerably reducing the cost of the experiment.  
The main findings from the study include: 
• 18,382 phosphorylation sites were identified with high confidence localization and 
quantified in cervix adenocarcinoma cells HeLa. 
• Phosphoproteomics analysis by HiRIEF requires low amount of material (300 
µg/sample) and allows for multiplex quantification using TMT. 
• 1,264 of the identified phospho-sites were novel.  
• A high proportion of tyrosine phosphorylation sites was identified: 1,203 pY sites (6.3% 
of all the identified phospho-sites).  
• HiRIEF fractionation using an IPG strip pH range 2.5-3.7 provides for enrichment of 
multiply phosphorylated peptides.  
• 165 novel phospho-sites with a putative regulatory function during mitotic progression 
were identified by kinase association analysis. 
Employment of a wide pH range (2.5-3.7 and 3-10) for fractionation resulted in the 
identification of phospho-peptides with both acid and basic amino acid composition (Figure 
13B), highly increasing the depth of the analysis as compared to the workflow presented in 
Study II.  
Specifically, the amino acid composition of the phospho-peptides impacts their distribution 
across HiRIEF fractions; very acidic phospho-peptides (DE>KHR) are identified in the pH 
range 2.5-3.7 strip and in the first 15 fractions of the pH range 3-10 strip, while basic 
phospho-peptides (DE<KR) are identified after fraction 15 of the IPG 3-10 strip (Figure 14). 
A possible improvement for future studies would be to reduce the extent of fractionation in 
order to decrease the analysis time, especially in the case of the IPG strip pH range 2.5-3.7, 
which has a relatively low complexity (6,537 phospho-peptides identified). In such a reduced 
fractionation protocol, keeping a separation between multiply phosphorylated and singly 
phosphorylated peptides (fractions 10-25 and fractions 40-72, respectively) would be 
beneficial in order to avoid the suppression of multiply phosphorylated peptide ionization by 
the singly phosphorylated peptides. 
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 An important issue that was addressed in this study concerns phospho-site functionality: as 
of today, only 3% of the reported human phosphorylation sites have a known regulatory 
function (total reported human phospho-sites: 224,661, corresponding to 17,495 gene 
products; reported regulatory phospho-sites: 6,695, corresponding to 2,187 gene products; 
PhosphoSitePlus, release 2017-07-19 [199]). In this study, phospho-site functionalities were 
predicted based on their strengths of interaction with protein kinases using NetworKIN 
[200,201], identifying 165 novel phospho-sites with a putatively regulatory function during 
mitosis. A limitation of this analysis is that the prediction is restricted to known protein 
kinase–substrate interactions. As discussed in paragraph 2.1.4 in the Methods section, the 
knowledge on protein kinases substrates is still partial, and association to substrates is not 
predicted for 311 of the 518 known human protein kinases. Consequently, the analysis is 
blind to the identification of functional phospho-sites that are phosphorylated by under-
studied protein kinases, whose substrate consensus motif and/or interaction partners are not 
yet known. 
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Figure 13. Distribution across the pI range of phospho-peptides based on their amino acid 
composition. A) 1 mg of peptides were separated on an IPG 2.5-3.7 strip in Study II to achieve 
phospho-enrichment; no TiO2 phospho-enrichment was performed. The plot represents only 
phosphorylated peptides (3,892 phospho-peptides, from replicate #2). B) TiO2 enriched peptides  
were further separated on IPG 2.5-3.7 and 3-10 strip in Study III. The plot represents only 
phosphorylated peptides (6,537 phospho-peptides in the IPG 2.5-3.7 and 15,294 phospho-peptides in 
the IPG 3-10). 
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Figure 14. Distribution of unique phospho-peptides across HiRIEF fractions, broken down by 
amino acid composition. Phospho-peptides were enriched by TiO2 prior to separation by HiRIEF 
(Study III). A) IPG 2.5-3.7; most identified phospho-peptides are very acidic (DE > KHR). The small 
number of phospho-peptides with a more basic amino acid composition identified in this pH range are 
multiply phosphorylated (fractions 10 to 25, see Fig. 2B in Paper III).  B) IPG 3-10; the distribution 
clearly shows a separation between acidic phospho-peptides (DE > KHR), identified predominantly 
before fraction 15, and basic phospho-peptides (DE < KR), identified predominantly after fraction 15. 
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 GENERAL CONCLUSIONS AND FUTURE 
PERSPECTIVES 
 
1 General conclusions 
This thesis focuses on investigating protein level regulatory mechanisms that contribute to the 
development of cancer, by applying and optimizing targeted and large-scale methods.  
In Study I, targeted methods for the analyses of protein stability, protein localization and 
protein-protein interactions allowed to describe a mechanism by which S100A4 interacts with 
p53 in the nucleus thereby promoting its degradation, in lung and cervix adenocarcinoma 
cells. 
In Studies II and III, the main objective was to optimize a workflow for phosphoproteomic 
analysis that would provide improvements over current methods, and to apply this workflow. 
In Study II, proteomics and phosphoproteomics analyses combined with targeted methods 
were employed to demonstrate that TRAP promotes metastasis-related cell properties in 
breast cancer cells via the TGFβ-pathway and CD44. In this study, a moderate-depth 
phosphoproteomic profiling of TRAP overexpressing cells was achieved by peptide 
fractionation by HiRIEF on IPG strips pH range 2.5-3.7, and provided a list of putative 
targets of TRAP phosphatase activity. In Study III, a workflow for in-depth quantitative 
phosphoproteomics analysis employing high-resolution isoelectric focusing (HiRIEF) 
fractionation on a wide pH range (2.5-10) was optimized. The workflow employs phospho-
enrichment by titanium dioxide coupled with isobaric labeling by TMT, and provides for 
good analytical depth and sensitivity, requiring a low amount of starting material. Application 
of this workflow for the analysis of cervix adenocarcinoma cells HeLa revealed 1,264 novel 
phosphorylation sites, of which 165 phospho-sites that are suggested to have a regulatory 
function during the mitotic phase based on kinase-association analysis. 
2 Future perspectives for the integration of large-scale and targeted 
methods 
The investigation of different mechanisms of protein level regulation relies on the existence 
of dedicated analytical approaches. The work presented in this thesis contributes to the 
collective effort of improving these methods by focusing on the optimization of a workflow 
for phosphoproteomics analysis. Considering the proteomics field at large, an array of 
methods for the large-scale analysis of protein levels [119,209–213], post-translational 
modifications [214–219], protein-protein interactions [220–229], protein stability [230–233] 
and subcellular localization [230,234,235] exists. These methods can further be improved in 
terms of proteome coverage, lowering the amount of material and time required for the 
analysis, as well as providing the possibility to analyze a larger number of samples.  
In the last decade, large-scale methods increasingly became important for biological research. 
Large-scale methods offer the possibility to obtain an unbiased global profiling of the system 
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being investigated. Large-scale methods for genomics and transcriptomics analysis have 
reached a significant level of maturity. The human genome project was initiated in 1990 and 
the first drafts of the human genome were published in 2001 [236,237]. Since then, extensive 
research efforts in the fields of genomics and transcriptomics led to the creation of resources 
that allow browsing of the human genome, both in a healthy state (UCSC Genome Browser 
[238]; https://genome.ucsc.edu) and in cancer (The Cancer Genome Atlas, TCGA [239,240]; 
https://cancergenome.nih.gov). The TCGA includes genomic maps of 33 types of cancer, 
generated from tumor tissues and matched normal tissues derived of more than 11,000 
patients, corresponding to the astronomic total of 2.5 petabytes of data. 
The proteomic field is much younger than the genomic field. The first publications containing 
the terms “human proteomic” and “human genomic” date back to 1992 and 1946, 
respectively, and the total number of publications in the field of genomic surpasses the ones 
in the field of proteomic by one order of magnitude (Table 2). 
Search term Number of publications Year of first entry 
Human proteomic 53,695 1992 
Human phosphoproteomic 1,457 2001 
Human genomic 697,769 1946 
Cancer proteomic 20,831 1996 
Cancer phosphoproteomic 775 2001 
Cancer genomic 266,708 1951 
 
Table 2. Number of publications in the proteomic and genomic field. The indicated terms were 
searched in Pubmed on August 25, 2017 (https://www.ncbi.nlm.nih.gov/pubmed). 
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Promisingly, the number of publications in the proteomic field has been increasing rapidly in 
the last 10 years (Figure 15), and the first drafts of the human proteome were published in 
2014 and in 2015, based on mass spectrometry analysis [117,241] and on microarray-based 
immunohistochemistry [118], respectively. Further developments of proteomics technology 
will be important to improve the description of the molecular phenotypes of biological 
systems, which cannot be obtained from genomic and transcriptomics analyses. 
The emergence of large-scale methods is resulting in the generation of biological data faster 
than ever before, and the scientific community is currently faced with the challenge of 
transforming this enormous amount of data in biological understanding. An estimation of the 
ultimate impact of large-scale data can be provided by the examination of the number of 
drugs approved by the Food and Drug Administration (FDA) in recent years.  
Figure 16 represents the number of approved drugs in the category “Other antineoplastic 
agents”. This category has been the fastest growing during the last 5 years [242], and includes 
monoclonal antibodies and kinase inhibitors, drugs that can be assigned to defined protein 
targets (other categories of antineoplastic drugs contain compounds that act as cytotoxic 
agents). Specifically, in this category twenty protein kinase inhibitors have been approved 
between 2011 and 2015. Even though these figures are positive, and despite the exponential 
growth of approved cancer drugs with well-defined targets, the absolute numbers of drugs 
being approved are still relatively small compared to the amount of biological data that is 
being produced. Additionally, the targets of FDA approved cancer drugs overlap only 
marginally with the cancer drivers discovered by genomic analyses, due to the fact that many 
of these cancer drivers are newly discovered cancer-associated genes on which little 
biological investigation has been performed [242,243] (Figure 17). Altogether, this data 
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highlights the need of improving the efficiency of generating biological understanding from 
large-scale data. 
 
In order to dissect this problem, consider the scheme presented in Figure 18. This schematic 
representation allows to decompose and analyze the different steps involved in the process 
leading from the production of large-scale data to the generation of novel biological 
understanding, and the expertise involved in each step. Data are generated by large-scale 
analyses (discovery phase); from the data, information is extracted by computational analyses 
(hypothesis building phase); the information is in turn used to produce mechanistic 
knowledge on the biological system being analyzed by targeted analyses (validation phase). 
Each step of this process requires different expertise. Successful completion of the process 
leads to the generation of novel biological understanding (i.e. explanation of a biological or 
molecular mechanism or process).  
As of today, the scientific community is quite successful in converting data into information, 
which is made available in databases, or presented in scientific publications as hypothetical 
biological models. The conversion of such information into knowledge and subsequently into 
biological understanding though is lagging behind due to the contributions of different 
factors, including:  
1) Lack of high throughput validation methods. Most of the methods currently available for 
targeted validation are low throughput. Very few methods exist that allow targeted 
analyses of a large number of samples in a limited time exist, e.g. luminex assays [244], 
proximity extension assays [245] and targeted proteomics [246]. Additional methods are 
Figure 17. Overlap of FDA approved cancer drug targets with cancer drivers identified by 
genomic analyses. The 154 cancer drugs represented on the left hand side of the figure include broadly 
cytotoxic agents, such as DNA intercalating agents, cytotoxic agents that act by modulating a target 
protein that is not unique of cancer cells such as tubulin inhibitors, and targeted agents that have a clear, 
tumor-specific target such as kinase inhibitors and nuclear hormone receptor antagonists. The targets of 
the drugs contained in the latter group (109 cancer targets) were compared with a consensus reference 
list of cancer driver genes [243]. Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Drug 
Discovery 16(1):19-34. A comprehensive map of molecular drug targets, Santos R et al.; doi: 10.1038/nrd.2016.230. Copyright 
2016. 
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necessary to probe the roles of candidate molecules in determining the observed 
phenotypes, and prioritize their selection for further analyses. 
2) Low level of integration between computationally-oriented and targeted biology-oriented 
research efforts. As of today, large-scale analyses and targeted analyses are often 
performed by distinct research groups. Groups performing targeted analyses often lack 
the expertise required to formulate biological questions based on large-scale data; 
similarly, groups performing large-scale analyses tend to have a strong computational 
component and do not follow-up their studies past the stage of formulating hypotheses. 
The result is a divide in the flow leading to the generation of biological understanding, 
which strongly hinders the successful completion of the process. Different measures can 
be taken to address this issue, including: 
• creation of mixed research groups, including both scientists with computational and 
wet lab skills, to promote communication and exchange of ideas 
• promoting the learning and the application of computational skills in wet lab research 
training positions, to reduce the distance between scientists with different expertise    
 
Figure 18. The interrupted flow of biological sciences. Schematic representation of the steps 
involved in the generation of novel biological understanding starting from large-scale biological data. 
The red double-funnel shape symbolically represents the current bottleneck in biological research, 
which, once overcome, will facilitate the use of the full potential of large-scale data.  The methods, 
goals and disciplines involved in each step of the process are listed below the schematic of the flow. 
Logical dissection of the flow into its components provides a framework to address current 
shortcomings and to develop ways to address the bottleneck and increase the generation of novel 
biological understanding.  
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In conclusion, this is an incredibly exciting time for biological research. Large-scale methods 
provide unprecedented opportunities for increasing our understanding of life and to discover 
new treatments and cures for diseases. Major challenges lying ahead involve the sphere of 
methodological improvements (both for large-scale analyses, e.g. proteomics, and for 
targeted analyses) and progresses of the current models of research towards a higher level of 
integration of different areas of expertise.  
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